{"id":"valganciclovir-valcyte","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valganciclovir is rapidly hydrolyzed in the intestine and liver to ganciclovir, its active form. Ganciclovir is phosphorylated by viral kinases (particularly CMV-encoded kinases) to form ganciclovir triphosphate, which inhibits CMV DNA polymerase and prevents viral DNA synthesis. This selective mechanism allows it to target CMV-infected cells while minimizing effects on uninfected host cells.","oneSentence":"Valganciclovir is a prodrug that is converted to ganciclovir, which inhibits viral DNA polymerase and prevents replication of cytomegalovirus (CMV).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:42:11.990Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cytomegalovirus (CMV) retinitis in immunocompromised patients (including HIV/AIDS)"},{"name":"CMV disease prevention in high-risk transplant recipients"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ACINETOBACTER TEST POSITIVE"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"BLOOD CREATINE INCREASED"},{"count":1,"reaction":"BLOOD LACTATE DEHYDROGENASE INCREASED"},{"count":1,"reaction":"BLOOD LACTIC ACID INCREASED"},{"count":1,"reaction":"COMPLICATION ASSOCIATED WITH DEVICE"},{"count":1,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":1,"reaction":"CYTOMEGALOVIRUS INFECTION"}],"_approvalHistory":[],"publicationCount":1831,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Treatment for CMV"],"phase":"marketed","status":"active","brandName":"valganciclovir [Valcyte]","genericName":"valganciclovir [Valcyte]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valganciclovir is a prodrug that is converted to ganciclovir, which inhibits viral DNA polymerase and prevents replication of cytomegalovirus (CMV). Used for Cytomegalovirus (CMV) retinitis in immunocompromised patients (including HIV/AIDS), CMV disease prevention in high-risk transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}